NYSE:PFEPharmaceuticals
Pfizer Inc. (NYSE:PFE) Looks Interesting, And It's About To Pay A Dividend
It looks like Pfizer Inc. ( NYSE:PFE ) is about to go ex-dividend in the next four days. The ex-dividend date is...
NasdaqCM:ATRSPharmaceuticals
Even though Antares Pharma (NASDAQ:ATRS) has lost US$51m market cap in last 7 days, shareholders are still up 69% over 5 years
Antares Pharma, Inc. ( NASDAQ:ATRS ) shareholders might be concerned after seeing the share price drop 12% in the last...
NasdaqGS:CBAYPharmaceuticals
Insider Buying: The CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Chief Medical Officer Just Bought US$61k Worth Of Shares
Even if it's not a huge purchase, we think it was good to see that Dennis Kim, the Chief Medical Officer of CymaBay...
NasdaqGS:VTYXPharmaceuticals
We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
NasdaqCM:PCSAPharmaceuticals
We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NYSE:MRKPharmaceuticals
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
NasdaqGS:ITCIPharmaceuticals
Those who invested in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago are up 230%
Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) shareholders have seen the share price descend 15% over the month. But...
NasdaqGM:OCULPharmaceuticals
Are Institutions Heavily Invested In Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Shares?
Every investor in Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) should be aware of the most powerful shareholder groups...
NasdaqCM:NTRBPharmaceuticals
Investors three-year losses grow to 80% as the stock sheds US$12m this past week
Over the last month the Nutriband Inc. ( NASDAQ:NTRB ) has been much stronger than before, rebounding by 62%. But that...